US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuveen Minnesota Municipal Income Fund

11.67

-0.0200-0.17%

Post-market: 11.670.00000.00%16:05 EDT

Volume:13.94K

Turnover:162.86K

Market Cap:67.53M

PE:-5.02

High:11.70

Open:11.68

Low:11.64

Close:11.69

Loading ...

Overview Company News Filings

Press Release: FatPipe Announces Leadership Team Appointments as It Accelerates Expansion Following Nasdaq Listing

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Press Release: Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for March 2025, includes Reg.-NMS Execution Statistics

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Oracle Empowers Utilities with New Advanced Distribution Management System Enhancements

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for February 2025, includes Reg.-NMS Execution Statistics

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Press Release: Franklin Access Appoints Ira Greenstein to Board of Directors

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for January 2025, includes Reg.-NMS Execution Statistics

Franklin Access Secures Funding for Sigbeat Joint Venture, Advancing 4G/5G and AI Module Innovation

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Nanoveu granted US patent to protect EMASS real-time object detection technology

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for November 2024, includes Reg.-NMS Execution Statistics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NMS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMS\",,,,,undefined,":{"symbol":"NMS","market":"US","secType":"STK","nameCN":"Nuveen Minnesota Municipal Income Fund","latestPrice":11.67,"timestamp":1747425600000,"preClose":11.69,"halted":0,"volume":13942,"hourTrading":{"tag":"盘后","latestPrice":11.67,"preClose":11.67,"latestTime":"16:05 EDT","volume":3,"amount":35.01,"timestamp":1747425914280},"delay":0,"floatShares":0,"shares":5787057,"eps":-2.32397,"marketStatus":"Market Closed","change":-0.02,"latestTime":"05-16 16:00:00 EDT","open":11.68,"high":11.7,"low":11.64,"amount":162856.740755,"amplitude":0.005133,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.32397,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747641600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":11.69,"dividendRate":0.075578,"postHourTrading":{"tag":"盘后","latestPrice":11.67,"preClose":11.67,"latestTime":"16:05 EDT","volume":3,"amount":35.01,"timestamp":1747425914280},"volumeRatio":0.8778823125177135},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMS\",,,,,undefined,":{"symbol":"NMS","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8778823125177135,"shares":5787057,"dividePrice":0.882,"high":11.7,"amplitude":0.005133,"preClose":11.69,"low":11.64,"week52Low":10.7323,"pbRate":"--","week52High":13.76,"institutionHeld":0,"latestPrice":11.67,"eps":-2.32397,"divideRate":0.075578,"volume":13942,"delay":0,"ttmEps":-2.32397,"open":11.68,"prevYearClose":12.34,"prevWeekClose":11.7,"prevMonthClose":11.73,"prevQuarterClose":12.0025,"fiveDayClose":11.7,"twentyDayClose":11.585,"sixtyDayClose":12.4052},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534453974","title":"Press Release: FatPipe Announces Leadership Team Appointments as It Accelerates Expansion Following Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534453974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534453974?lang=en_us&edition=fundamental","pubTime":"2025-05-10 00:58","pubTimestamp":1746809880,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, May 9, 2025 /PRNewswire/ -- FatPipe, Inc. FatPipe, Inc.  , a pioneer in enterprise-class, application-aware, secure software-defined wide area network  solutions that provide the highest levels of reliability, security, and optimization for Wide Area Networks , today announced the appointment of its full executive management team as it continues to build on the momentum of its recent Nasdaq listing, scaling operations globally to meet increasing demand for secure, reliable, and optimized enterprise connectivity.\"While our innovative solutions remain the foundation of our success, our world-class leadership team is a key driver of FatPipe's competitive advantage,\" said Dr. Ragula Bhaskar, Chairman and CEO of FatPipe. \"With decades of combined expertise in networking technology, cybersecurity, sales, and finance, we have built a leadership team ready to drive FatPipe's next phase of growth. Together, we are focused on expanding our talent base and seizing opportunities in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4023","BK4588","LU2210150020.SGD",".IXIC","IE00BGHQF748.EUR","NDAQ","NQmain","NMS","TISI","BK4112","BK4585","FATN","IE00BKPKM429.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4120"],"gpt_icon":0},{"id":"2530699827","title":"Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2530699827","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530699827?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:05","pubTimestamp":1745525100,"startTime":"0","endTime":"0","summary":"Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern. SAN DIEGO, April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term safety profile and robust efficacy of INGREZZA  capsules in adults aged 65 years and older with tardive dyskinesia  inThe Journal of Clinical Psychiatry. This represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment ofTD in older adults , a group at higher risk for TD and associated consequences.\"This analysis, the first and only of its kind in a peer-reviewed publication, addresses an important gap in research on this potentially vulnerable population,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurocrine-biosciences-publishes-analysis-showing-200500549.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurocrine-biosciences-publishes-analysis-showing-200500549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1069344957.HKD","LU1551013425.SGD","LU0820562030.AUD","LU1035775433.USD","LU1914381329.SGD","LU0820561818.USD","LU2756315318.SGD","BK4533","LU1778281490.HKD","NBIX","SG9999001440.SGD","TD","LU0868494617.USD","LU0943347566.SGD","LU0823411888.USD","LU1093756168.USD","LU0823416689.USD","LU0320765992.SGD","LU1929549753.HKD","BK4139","LU1093756325.SGD","BK4585","NMS","BK4581","LU1989772840.SGD","IE00BSNM7G36.USD","LU1674673428.USD","IE00BZ1G4Q59.USD","LU1162221912.USD","LU0889565916.HKD","LU2065171311.SGD","IE00BWXC8680.SGD","LU1551013342.USD","LU2324357040.USD","BK4567","BK4083","BK4588","BK4550","LU1989772923.USD","LU0354030438.USD","BK4534","LU2065169927.USD","BK4504","HD","LU0234572021.USD","BK4207","LU0354030511.USD","IE00B1XK9C88.USD","LU2065170008.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2524149807","title":"Press Release: Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2524149807","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524149807?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:44","pubTimestamp":1743597840,"startTime":"0","endTime":"0","summary":"Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership. Advances Company's industry-leading portfolio in mental health with addition of CAPLYTA , the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults. sNDA submitted to U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care for most common depressive disorders. Addition of CAPLYTA strengthens J&J's robust lineup of therapies with $5 billion+ potential in peak year sales , further solidifying sales growth above analyst expectations now through the remainder of the decade. Johnson & Johnson  today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnso","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TD","LU2430703251.USD","LU1023059063.AUD","LU0109394709.USD","BK4566","LU0122379950.USD","BK4585","LU1162221912.USD","IE00B3T34201.USD","LU1074936037.SGD","LU0234572021.USD","BK4534","BK4588","LU2133065610.SGD","NMS","SG9999002224.SGD","IE00B3PB1722.GBP","LU0203345920.USD","LU1221951046.USD","IE00B7SZLL34.SGD","LU0792757196.USD","IE0002270589.USD","LU0345770308.USD","JNJ","LU2430703178.SGD","BK4559","IE00BGHQF631.EUR","BK4211","ITCI","LU1914381329.SGD","LU1244550494.USD","IE00BJJMRZ35.SGD","IE0034235303.USD","LU0058720904.USD","SG9999001440.SGD","LU0889566641.SGD","R","LU1430594728.SGD","IE00B19Z3B42.SGD","LU1929549753.HKD","IE00BVYPNV92.GBP","LU1032466523.USD","LU1061106388.HKD","LU0098860793.USD","IE00BDGV0183.EUR","LARK","LU0320765646.SGD","LU0345770993.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2524607144","title":"Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for March 2025, includes Reg.-NMS Execution Statistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2524607144","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524607144?lang=en_us&edition=fundamental","pubTime":"2025-04-02 00:40","pubTimestamp":1743525600,"startTime":"0","endTime":"0","summary":"GREENWICH, Conn., April 01, 2025----Interactive Brokers Group, Inc.  an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for March.Ending client equity of $573.5 billion, 23% higher than prior year and 2% lower than prior month.Ending client margin loan balances of $63.7 billion, 24% higher than prior year and about even with prior month.Ending client credit balances of $125.2 billion, including $4.9 billion in insured bank deposit sweeps2, 19% higher than prior year and 1% higher than prior month.The real account growth in March was 87.7 thousand accounts vs the calculated change in accounts of 74.4 thousand. The difference is attributable to 13.3 thousand accounts that were escheated to governmental authorities, as required by law.211 annualized average cleared DARTs1 per client account.Average commission per cleared Commissionable Order3 of $2.85 including exchange, clearing and regulatory fees. Key products:. IBKR PRO Clients' ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interactive-brokers-group-reports-brokerage-164000816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NMS","BK4585","LU0971096721.USD","LU1363072403.SGD","LU0963586101.USD","IBKR","BK4134","LU2237957902.USD","BK4127","III","BK4588","LU2237957811.SGD","BK4598"],"gpt_icon":1},{"id":"2523949949","title":"Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949949","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949949?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"All Patients Treated with INGREZZA  Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months. Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting. SAN DIEGO, March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA  capsules upon initiation of treatment. This retrospective cohort study will be presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting in Houston, Texas.\"These findings provide critical insights into the real-world use of VMAT2 inhibitors in treating tardive dyskinesia,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. \"Significant differences were observed between INGREZZA and deutetrabenazine in reaching therapeutic doses. The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurocrine-biosciences-presents-real-world-123000519.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurocrine-biosciences-presents-real-world-123000519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU0320765992.SGD","LU1496350502.SGD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0354030511.USD","LU0820562030.AUD","LU0109394709.USD","LU1551013342.USD","BK4585","LU0689472784.USD","BK4588","LU2324357040.USD","HD","LU1551013425.SGD","LU1674673691.USD","LU0943347566.SGD","LU0823416689.USD","LU0823434583.USD","BK4534","IE00BWXC8680.SGD","LU1674673428.USD","LU1496350171.SGD","BK4504","LU2756315664.SGD","IE00BZ1G4Q59.USD","BK4581","LU2065171311.SGD","BK4139","NMS","LU1035775433.USD","LU0320765646.SGD","LU0234572021.USD","LU1069344957.HKD","LU0820561909.HKD","LU0868494708.USD","LU1778281490.HKD","LU1914381329.SGD","TD","IE00B1XK9C88.USD","LU0354030438.USD","LU0942090050.USD","BK4207","BK4567","LU2065170008.USD","NBIX","LU0820561818.USD","BK4083","LU0823434740.USD","BK4566"],"gpt_icon":0},{"id":"2522222290","title":"Oracle Empowers Utilities with New Advanced Distribution Management System Enhancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2522222290","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522222290?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Modern, scalable grid operations expand distributed energy resource orchestration, improve forecasting, and optimize reliability. DALLAS, March 25, 2025 /PRNewswire/ -- DISTRIBUTECH--Oracle today announced new Oracle Utilities Network Management System features to help control room operators and program managers manage distributed energy resources  throughout their lifecycle. These ADMS enhancements help utilities alleviate grid stress through better demand response and DER management while optimizing performance using both front-of-the-meter and behind-the-meter data and tools. New innovations also help users address increasing extreme weather events with rapid response, restoration, and decentralization.Used by six of the top 10 U.S. utilities and supporting over 61 million customers, Oracle Utilities NMS offers a single, unified model to help optimize grid performance and integrate renewable energy resources. The modular and composable architecture—combining outage, distribution, DE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oracle-empowers-utilities-advanced-distribution-120000240.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oracle-empowers-utilities-advanced-distribution-120000240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565833.HKD","IE0002270589.USD","LU0082616367.USD","LU0648001328.SGD","LU1035773651.USD","LU0175139822.USD","LU0417517546.SGD","BK4182","BK4543","LU1506573853.SGD","IE00B19Z4B17.USD","IE0009356076.USD","ORCL","BESS","LU0861579265.USD","LU1989764748.USD","LU1201861249.SGD","LU1935042215.USD","LU2054465674.USD","IE00BMPRXR70.SGD","BK4097","LU1934455277.USD","AEIS","IE00B19Z3581.USD","IE0004445239.USD","IE00B7SZLL34.SGD","LU0661504455.SGD","LU0719512351.SGD","BK4581","LU1642822529.SGD","LU0234570918.USD","BK4538","LU0985489474.SGD","IE00BLSP4452.SGD","LU0348723411.USD","LU0444973449.USD","LU0878866978.SGD","LU1429558221.USD","LU2236285917.USD","BK4534","LU0323591593.USD","NMS","IE00BLSP4239.USD","LU1935043023.USD","LU0208291251.USD","LU1489326972.SGD","BK4516","BK4533","LU0256863811.USD","LU0320765489.SGD"],"gpt_icon":1},{"id":"2520645743","title":"Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2520645743","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520645743?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:30","pubTimestamp":1742473800,"startTime":"0","endTime":"0","summary":"Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder. Findings Presented at the 2025 Psychiatry Update Conference. SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA  capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.\"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition, including schizophrenia, schizoaffective disorder or mood disorder,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. \"The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of INGREZZA, at e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurocrine-biosciences-presents-48-week-123000532.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurocrine-biosciences-presents-48-week-123000532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823434583.USD","BK4207","BK4139","LU0868494708.USD","LU1989772840.SGD","LU0079474960.USD","LU2065171402.SGD","BK4083","IE00BKVL7J92.USD","LU0320765992.SGD","LU0942090050.USD","IE00BWXC8680.SGD","IE00B1XK9C88.USD","LU0354030438.USD","NBIX","LU1778281490.HKD","LU0889565916.HKD","LU0823411888.USD","LU1674673428.USD","LU2065171311.SGD","LU0943347566.SGD","LU0823434740.USD","LU1674673691.USD","BK4581","LU1093756325.SGD","LU1496350171.SGD","BK4534","LU2756315664.SGD","BK4533","LU2756315318.SGD","LU1162221912.USD","LU0234572021.USD","LU0820561818.USD","LU2065169927.USD","LU2065170008.USD","LU0320765646.SGD","TD","HD","IE00BSNM7G36.USD","LU0820562030.AUD","LU0820561909.HKD","LU1035775433.USD","LU0109394709.USD","LU1093756168.USD","BK4567","IE00BZ1G4Q59.USD","LU1551013425.SGD","NMS","LU0689472784.USD","LU1496350502.SGD"],"gpt_icon":0},{"id":"2519002866","title":"Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519002866","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519002866?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:02","pubTimestamp":1741896120,"startTime":"0","endTime":"0","summary":"Q4 2024 revenue increased 24.6%over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042576/28255/en/Evoke-Pharma-Inc-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","BK4588","BK4566","LU0390134368.USD","NMS","CRL","BK4207","BK4007","BK4121","BK4585","TD","EVOK"],"gpt_icon":0},{"id":"2516651936","title":"Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for February 2025, includes Reg.-NMS Execution Statistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516651936","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516651936?lang=en_us&edition=fundamental","pubTime":"2025-03-04 02:00","pubTimestamp":1741024800,"startTime":"0","endTime":"0","summary":"GREENWICH, Conn., March 03, 2025----Interactive Brokers Group, Inc.  an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for February.Ending client equity of $587.8 billion, 31% higher than prior year and 1% lower than prior month.Ending client margin loan balances of $63.3 billion, 34% higher than prior year and 2% lower than prior month.Ending client credit balances of $123.8 billion, including $4.8 billion in insured bank deposit sweeps2, 20% higher than prior year and 3% higher than prior month.225 annualized average cleared DARTs1 per client account.Average commission per cleared Commissionable Order3 of $2.80 including exchange, clearing and regulatory fees. Key products:. Average U.S. Reg-NMS stock trade was $18,841 in February .In February, IBKR PRO clients’ total cost of executing and clearing U.S. Reg.-NMS stocks through IB was about 3.1 basis points of trade money5, as, measured against a daily VWAP6 benchmark .IBKR PRO ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interactive-brokers-group-reports-brokerage-180000556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237957902.USD","IBKR","BK4588","LU1363072403.SGD","LU0971096721.USD","BK4134","LU2237957811.SGD","NMS","BK4127","LU0963586101.USD","BK4585","III"],"gpt_icon":0},{"id":"2514358730","title":"Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358730","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358730?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 27, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc.  today announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA  capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia , irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional impact of involuntary movements. These patient-reported outcome measures provide a more complete perspective on a patient's experience of living with TD and the broad range of improvements that occurred following treatment with INGREZZA. The results of KINECT-PRO will be shared at upcoming scientific conferences.Results showed signif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurocrine-biosciences-reports-patient-reported-210500144.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurocrine-biosciences-reports-patient-reported-210500144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1778281490.HKD","LU1093756168.USD","LU0820561818.USD","LU1496350171.SGD","LU2065171311.SGD","NBIX","LU0079474960.USD","SDS","HD","LU0823434583.USD","LU0354030438.USD","LU1989772923.USD","PRO","NMS","BK4567","LU0868494708.USD","LU1914381329.SGD","TD","LU1035775433.USD","LU0320765646.SGD","BK4566","LU0820562030.AUD","LU1551013425.SGD","LU1674673691.USD","LU2065171402.SGD","LU0823416689.USD","BK4207","LU0354030511.USD","LU1674673428.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU0820561909.HKD","BK4023","LU0868494617.USD","LU1551013342.USD","LU1162221912.USD","LU1929549753.HKD","BK4083","BK4588","BK4534","BK4504","LU2065170008.USD","IE00B1XK9C88.USD","SG9999001440.SGD","BK4581","IE00BWXC8680.SGD","LU1069344957.HKD","LU0823434740.USD","LU0234572021.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2514049119","title":"Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2514049119","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514049119?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:00","pubTimestamp":1740517200,"startTime":"0","endTime":"0","summary":"UZEDY is currently approved in the US as a subcutaneous long-acting injectable  for use every one or two months for the treatment of schizophrenia in adults1. LAI treatment options may help address unmet needs of people living with bipolar I disorder . BP-I filing acceptance for UZEDY represents Teva’s commitment to pursuing new advances in neuroscience. The sNDA is based on leveraging the existing clinical data for UZEDY coupled with the Agency’s previous findings of safety and efficacy of past risperidone formulations approved for the treatment of BP-I.Teva will lead the regulatory process and be responsible for potential commercialization of UZEDY for BP-I, with Medincell eligible for royalties on net sales.About Bipolar I DisorderBipolar Disorder I  is a manic-depressive condition that leads to large swings in mood and actions that greatly impact quality of life and ability to complete day-to-day tasks. It is challenging to diagnose and is often accompanied by other psychiatric com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-medincell-announce-fda-acceptance-210000180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","R","TD","BK4232","TEVA","BK4585","RISE","DM","BK4546","BK4007","MDCLF","NMS","BK4566","BK4207","BK4161"],"gpt_icon":0},{"id":"2513126032","title":"Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2513126032","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513126032?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:00","pubTimestamp":1740142800,"startTime":"0","endTime":"0","summary":"Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/21/3030430/30597/en/Intra-Cellular-Therapies-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI","LU1169589451.USD","BK4135","LU0012050646.USD","LU0889565916.HKD","LU1169590202.USD","LU0109394709.USD","PD","NMS","CNS","BK4007","BK4023","LU0320765992.SGD","LU0053671581.USD","LU0106261612.USD"],"gpt_icon":0},{"id":"2512688731","title":"Press Release: Franklin Access Appoints Ira Greenstein to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2512688731","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512688731?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:01","pubTimestamp":1739887260,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 18, 2025  -- Franklin Wireless Corp.  announces the appointment of Ira Greenstein to the Company's Board of Directors, effective February 17, 2025.\"We are pleased to welcome Ira Greenstein to the Company's Board of Directors,\" said OC Kim, President and CEO of Franklin Wireless. \"Ira's extensive legal, corporate, and government experience brings a new depth of knowledge, critical skills in strategic decision-making and governance to the board.\". Mr. Greenstein is a Founding Partner of the Pierson Ferdinand LLP law firm. He previously served as Deputy Assistant and Strategist to the President during the first Trump Administration. Before his government service, he was President of IDT Corporation and Genie Energy Ltd.Mr. Greenstein holds a Bachelor of Science degree from Cornell University's School of Industrial and Labor Relations and a Juris Doctor  from Columbia University School of Law. He is currently a member of the board of Forafric Global plc. , where he serves o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4558","LU0244354667.USD","BK4588","BK4504","TSYW.SI","LU1688375341.USD","SQQQ","NVIW.SI","QID","BK4585","USAW.SI","BK4122","BK4551","LU0307460666.USD","NMS","FELE","IE0008368742.USD","LU0463099449.HKD","BK4524","BK4212","NQmain","BK4220","TQQQ","LU1880383366.USD","LU2229751404.USD","LU0326950275.SGD","LU0106959298.USD","BK4020","BK4509","BK4505","LU2089279066.USD","QLD","BK4161","MNQmain","BK4526","AFRI","USJW.SI","BK4503","BK4531","LU1188198961.HKD","FKWL",".IXIC","LU0588546209.SGD","BK4579","SG9999002463.SGD","IE00BGV7N243.SGD","PSQ"],"gpt_icon":1},{"id":"2508512598","title":"Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for January 2025, includes Reg.-NMS Execution Statistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2508512598","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508512598?lang=en_us&edition=fundamental","pubTime":"2025-02-04 01:18","pubTimestamp":1738603080,"startTime":"0","endTime":"0","summary":"GREENWICH, Conn., February 03, 2025----Interactive Brokers Group, Inc.  an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for January.Ending client equity of $591.4 billion, 39% higher than prior year and 4% higher than prior month.Ending client margin loan balances of $64.9 billion, 47% higher than prior year and 1% higher than prior month.Ending client credit balances of $120.4 billion, including $4.7 billion in insured bank deposit sweeps2, 17% higher than prior year and 1% higher than prior month.223 annualized average cleared DARTs1 per client account.Average commission per cleared Commissionable Order3 of $2.59 including exchange, clearing and regulatory fees. Key products:. Average U.S. Reg-NMS stock trade was $18,967 in January .In January, IBKR PRO clients’ total cost of executing and clearing U.S. Reg.-NMS stocks through IB was about 2.6 basis points of trade money5, as, measured against a daily VWAP6 benchmark .IBKR PR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interactive-brokers-group-reports-brokerage-171800928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","LU1363072403.SGD","BK4134","IBKR","LU0963586101.USD","III","LU2237957902.USD","BK4127","LU2237957811.SGD","NMS","LU0971096721.USD"],"gpt_icon":0},{"id":"2505016181","title":"Franklin Access Secures Funding for Sigbeat Joint Venture, Advancing 4G/5G and AI Module Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2505016181","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505016181?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:00","pubTimestamp":1737640800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan.  23, 2025  (GLOBE NEWSWIRE) -- Franklin Access (NASDAQ: FKWL) announced today the successful funding of its joint venture to develop 4G/5G modules and AI-powered solutions under the Si","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014303/0/en/Franklin-Access-Secures-Funding-for-Sigbeat-Joint-Venture-Advancing-4G-5G-and-AI-Module-Innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2229751404.USD","FKWL","BK4213","LU2089279066.USD","FELE","NMS","BK4020","JYNT","AR","BK4185","BK4161"],"gpt_icon":0},{"id":"2503237716","title":"Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503237716","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503237716?lang=en_us&edition=fundamental","pubTime":"2025-01-13 19:32","pubTimestamp":1736767920,"startTime":"0","endTime":"0","summary":"Acquisition includes CAPLYTA (lumateperone), the first and onlyU.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizoph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008254/30597/en/Johnson-Johnson-Strengthens-Neuroscience-Leadership-with-Acquisition-of-Intra-Cellular-Therapies-Inc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001440.SGD","LU2133065610.SGD","LU2244417387.USD","LU0889566641.SGD","BK4135","SG9999002224.SGD","LU0234572021.USD","LU1196500208.SGD","LU0203345920.USD","LU2098885051.SGD","LU0289739699.SGD","LU1066051498.USD","NMS","LU0106261612.USD","LU0053671581.USD","LU0742534661.SGD","NSC","LU0109394709.USD","BK4568","BK4550","LU0234570918.USD","LU0251131958.USD","BK4559","LU0795875169.SGD","IE00BDGV0183.EUR","IE00B2B36J28.USD","LU0320765646.SGD","LU1244550494.USD","LU1023059063.AUD","LU0466842654.USD","LU0114720955.EUR","LU1674673691.USD","IE00B42XCP33.USD","LU0640476718.USD","CNS","BK4504","LU1057294990.SGD","LU1261432733.SGD","IE0034235303.USD","ITCI","LU0012050646.USD","IE0002270589.USD","LU1430594728.SGD","LU1894683264.USD","LU0889565916.HKD","IE000M9KFDE8.USD","BK4016","LU1066051811.HKD","JNJ"],"gpt_icon":0},{"id":"2490842048","title":"Nanoveu granted US patent to protect EMASS real-time object detection technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2490842048","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490842048?lang=en_us&edition=fundamental","pubTime":"2024-12-12 10:52","pubTimestamp":1733971953,"startTime":"0","endTime":"0","summary":"Nanoveu  has been granted a key US patent to protect specialised solutions for real-time object detection and tracking developed by semiconductor business Embedded AI Systems .The exclusively licenced patent covers a novel non-maximum suppression  hardware block that measures only 0.06 square millimetres.That is more than 90% smaller than typical solutions.NMS has been designed to reduce the costs and complexity of EMASS’s proprietary chip technology.It can handle up to 10,000 “bounding boxes” per second while operating under 1 megawatt to significantly extend device battery life and slash energy costs.“By streamlining NMS at the hardware level, we can enable faster, smaller and more sustainable solutions,” he said.“Unlike standard NMS methods that struggle under real-time conditions, EMASS’s patented design can track multiple objects simultaneously with lower energy draw,” he said.EMASS will commence compatibility integration tests across various hardware and software ecosystems to co","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Nanoveu-ASX-NVU-USA-Patent-Next-Generation-Vision-AI-Hardware.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Nanoveu-ASX-NVU-USA-Patent-Next-Generation-Vision-AI-Hardware.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/nanoveu-us-patent-protect-emass-real-time-object-detection-technology/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7076","NMS","NVU.AU","BK7501"],"gpt_icon":0},{"id":"2490517238","title":"Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490517238","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490517238?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922000,"startTime":"0","endTime":"0","summary":"Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995339/30597/en/Intra-Cellular-Therapies-Presents-Data-from-the-CAPLYTA-Adjunctive-MDD-Phase-3-Program-at-the-American-College-of-Neuropsychopharmacology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","LU0012050646.USD","NMS","LU1880398471.USD","IE00B29SXK94.USD","LU0109394709.USD","BK4107","AFG","BK4007","BK4117","LU0106261612.USD","ES","ITCI","LU0053671581.USD","LU0889565916.HKD","LU2637428348.USD","IE00BZ18W456.USD","ADT","BK4585","BK4135","BK4081","IE00BZ18W340.USD","IE00BMG7P819.SGD","IE00BMG7P694.USD","LU1880398554.USD","BK4588","LU2449327464.USD","IE00BMG7P587.USD","BK4165","ABVC","IE00BMQBXF63.USD","IE00B29SXL02.USD","LU0320765992.SGD","BK4192","BK4139","IE00BMG7P926.USD","LU1883839398.USD","LU1803068623.USD"],"gpt_icon":0},{"id":"2488911630","title":"Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488911630","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488911630?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:30","pubTimestamp":1733229000,"startTime":"0","endTime":"0","summary":"The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990492/30597/en/Intra-Cellular-Therapies-Submits-Supplemental-New-Drug-Application-sNDA-to-FDA-for-CAPLYTA-lumateperone-for-the-Treatment-of-Major-Depressive-Disorder-as-Adjunctive-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","ITCI","BK4139","LU0106261612.USD","NMS","LU0012050646.USD","BK4007","ABVC","LU0053671581.USD","LU0109394709.USD","CNS","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2488996571","title":"Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for November 2024, includes Reg.-NMS Execution Statistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2488996571","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488996571?lang=en_us&edition=fundamental","pubTime":"2024-12-03 02:21","pubTimestamp":1733163660,"startTime":"0","endTime":"0","summary":"GREENWICH, Conn., December 02, 2024----Interactive Brokers Group, Inc.  an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for November.Ending client equity of $575.9 billion, 42% higher than prior year and 7% higher than prior month.Ending client margin loan balances of $60.2 billion, 43% higher than prior year and 2% higher than prior month.Ending client credit balances of $118.8 billion, including $4.7 billion in insured bank deposit sweeps2, 17% higher than prior year and 1% higher than prior month.227 annualized average cleared DARTs1 per client account.Average commission per cleared Commissionable Order4 of $2.70 including exchange, clearing and regulatory fees. Key products:. Average U.S. Reg-NMS stock trade was $20,291 in November .In November, IBKR PRO clients’ total cost of executing and clearing U.S. Reg.-NMS stocks through IB was about 2.8 basis points of trade money6, as, measured against a daily VWAP7 benchmark .IBKR","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fdnaGwC8UCpQlj_wnLXjPw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d22b695fb15bf9c6de008960af291ec2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fdnaGwC8UCpQlj_wnLXjPw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d22b695fb15bf9c6de008960af291ec2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interactive-brokers-group-reports-brokerage-182100372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBKR","BK4585","BK4134","NMS","III","LU0971096721.USD","LU1363072403.SGD","BK4588","BK4127","LU0963586101.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMS\",params:#limit:5,,,undefined,":[{"date":"2025-05-15","symbol":"NMS","amount":0.0735,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-15","defaultRemindTime":1747315800000,"name":"Nuveen Minnesota Municipal Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-02","payableDate":"2025-05-15","currency":"USD","dateTimestamp":1747281600000,"payDate":"2025-06-02"},{"date":"2025-04-15","symbol":"NMS","amount":0.0735,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Nuveen Minnesota Municipal Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-05-01"},{"date":"2025-03-14","symbol":"NMS","amount":0.0735,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-14","defaultRemindTime":1741959000000,"name":"Nuveen Minnesota Municipal Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-14","currency":"USD","dateTimestamp":1741924800000,"payDate":"2025-04-01"},{"date":"2025-02-14","symbol":"NMS","amount":0.0735,"announcedDate":"2025-02-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Nuveen Minnesota Municipal Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-03-03"},{"date":"2025-01-15","symbol":"NMS","amount":0.0735,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-15","defaultRemindTime":1736951400000,"name":"Nuveen Minnesota Municipal Income Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-03","payableDate":"2025-01-15","currency":"USD","dateTimestamp":1736917200000,"payDate":"2025-02-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMS\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-11","recordDate":"2015-06-15","paymentDate":"2015-07-01","value":0.069,"currency":"USD"},{"executeDate":"2015-07-13","recordDate":"2015-07-15","paymentDate":"2015-08-03","value":0.069,"currency":"USD"},{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-09-01","value":0.069,"currency":"USD"},{"executeDate":"2015-09-11","recordDate":"2015-09-15","paymentDate":"2015-10-01","value":0.0665,"currency":"USD"},{"executeDate":"2015-10-13","recordDate":"2015-10-15","paymentDate":"2015-11-02","value":0.0665,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMS\",market:\"US\",delay:false,,,undefined,":{}}}